Business Description
Cyclacel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US23254L4059
Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 91.3 | |||||
| Equity-to-Asset | 0.07 | |||||
| Debt-to-Equity | 0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -77.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12 | |||||
| 3-Year EPS without NRI Growth Rate | 20 | |||||
| 3-Year FCF Growth Rate | 17 | |||||
| 3-Year Book Growth Rate | -80.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.91 | |||||
| 9-Day RSI | 47.82 | |||||
| 14-Day RSI | 44.84 | |||||
| 6-1 Month Momentum % | -77.69 | |||||
| 12-1 Month Momentum % | -74.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.91 | |||||
| Quick Ratio | 0.91 | |||||
| Cash Ratio | 0.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -36.5 | |||||
| Shareholder Yield % | 1.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -6060.24 | |||||
| Net Margin % | -5370.24 | |||||
| FCF Margin % | -3837.62 | |||||
| ROE % | -227.33 | |||||
| ROA % | -128.37 | |||||
| ROIC % | -862.97 | |||||
| ROC (Joel Greenblatt) % | -17700.28 | |||||
| ROCE % | -254.78 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.7 | |||||
| PB Ratio | 3.25 | |||||
| Price-to-Tangible-Book | 3.25 | |||||
| EV-to-EBIT | 0.03 | |||||
| EV-to-EBITDA | 0.03 | |||||
| EV-to-Revenue | -1.86 | |||||
| EV-to-FCF | 0.05 | |||||
| Earnings Yield (Greenblatt) % | 3333.33 | |||||
| FCF Yield % | -661.12 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers